Kymera Therapeutics, Inc. (KYMR) Stock Analysis

Q: What is the KYMR stock price target?

Take-profit $107.23 (+32.9% upside). Prior stop was $75.31.

Q: What are the risks of investing in KYMR?

Concentration risk — Pipeline: STAT6, IRF5 and IRAK4 programs; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 6.10% of cap); Quality below floor (1.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 6.10% of cap).

Q: Is KYMR overvalued or undervalued?

Kymera Therapeutics, Inc. trades at a P/E of N/A (forward -20.3). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about KYMR?

29 analysts cover KYMR with a consensus score of 4.3/5. Average price target: $119.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-05-01

Healthcare · Biotechnology

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral targeted protein degraders for immunology. Lead programs include KT-621 (STAT6, Phase 2b in atopic dermatitis/asthma), KT-579 (IRF5, Phase 1), and KT-485 (IRAK4, Sanofi collaboration). CDK2 program... Read more

$80.99+32.9% A.UpsideScore 4.5/10#129 of 158 Biotechnology

Stop $75.31Target $107.23(analyst − 10%)A.R:R 3.6:1

Analyst target$119.14+47.1%21 analysts

$107.23our TP

$80.99price

$119.14mean

$140

Sell if holding. Engine safety override at $80.99: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.5/10, moderate confidence.

Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Pipeline: STAT6, IRF5 and IRAK4 programs

Quality below floor (1.5 < 4.0)

Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 6.10% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-20.3

Mkt Cap$6.7B

EV/EBITDA-17.4

Profit Mgn0.0%

ROE-25.8%

Rev Growth-61.2%

Beta2.29

DividendNone

Rating analysts29

Quality Signals

Piotroski F2/9

Options Flow

P/C0.69bullish

IV68%elevated

Max Pain$25-69.1% vs spot

Concentration Risks(10-K Item 1A)

HIGHpipelineSTAT6, IRF5 and IRAK4 programs
10-K Item 1A: 'We focus on a limited number of research programs and product candidates. We are currently focused on our immunology portfolio, consisting of our STAT6, IRF5 and IRAK4 programs'

Material Events(8-K, last 90d)

2026-02-26Item 1.02MEDIUM
Termination of prior at-the-market sales agreement in connection with entering new ATM agreement with TD Securities (USA) LLC for up to 500M shares. Commission up to 3.0%% of gross proceeds.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.515%0.22

Growth5.015%0.75

Momentum2.310%0.23

Sentiment6.410%0.64

Insider Activity3.410%0.34

Peer Rank3.510%0.35

Technical Setup6.85%0.34

Risk Profile2.55%0.13

Catalyst3.65%0.18

Overall (Σ contributions)4.53

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -347% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Obv

1.0

Volume

1.1

Ma Position

4.0

Rsi

5.5

Volume distribution (falling OBV)Above 200-day MA

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Days To Cover

0.0

Debt Equity

0.0

Volatility

1.1

Implied Vol

1.9

Beta

2.4

Short Interest

2.9

Max Pain Risk

3.0

Put Call

8.7

High IV: 68%Above max pain $25Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

1.4

Value Rank

5.0

Quality Rank

5.7

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

News Activity

8.0

Earnings concerns: 1B/3MEarnings in 0 days

GatesMomentum 2.3<4.5EARNINGS PROXIMITY 0d<=7dA.R:R 3.6 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

41 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $77.64Resistance $90.14

Price Targets

$75

$107

A.Upside+32.4%

A.R:R3.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)

! Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 6.10% of cap)

! Momentum score 2.3/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is KYMR stock a buy right now?

Sell if holding. Engine safety override at $80.99: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 3.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $75.31. Score 4.5/10, moderate confidence.

What is the KYMR stock price target?

Take-profit target: $107.23 (+32.9% upside). Prior stop was $75.31. Stop-loss: $75.31.

What are the risks of investing in KYMR?

Concentration risk — Pipeline: STAT6, IRF5 and IRAK4 programs; Quality below floor (1.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin 4.7%), Material insider selling (8 sells, 6.10% of cap).

Is KYMR overvalued or undervalued?

Kymera Therapeutics, Inc. trades at a P/E of N/A (forward -20.3). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about KYMR?

29 analysts cover KYMR with a consensus score of 4.3/5. Average price target: $119.

What does Kymera Therapeutics, Inc. do?Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral targeted protein degraders for...